Haeger, Anna, Alexander, Stephanie ORCID: 0000-0002-8308-3977, Vullings, Manon, Kaiser, Fabian M. P., Veelken, Cornelia, Flucke, Uta, Koehl, Gudrun E., Hirschberg, Markus, Flentje, Michael, Hoffman, Robert M., Geissler, Edward K., Kissler, Stephan and Friedl, Peter ORCID: 0000-0002-0119-4041 (2020). Collective cancer invasion forms an integrin-dependent radioresistant niche. J. Exp. Med., 217 (1). NEW YORK: ROCKEFELLER UNIV PRESS. ISSN 1540-9538

Full text not available from this repository.

Abstract

Cancer fatalities result from metastatic dissemination and therapy resistance, both processes that depend on signals from the tumor microenvironment. To identify how invasion and resistance programs cooperate, we used intravital microscopy of orthotopic sarcoma and melanoma xenografts. We demonstrate that these tumors invade collectively and that, specifically, cells within the invasion zone acquire increased resistance to radiotherapy, rapidly normalize DNA damage, and preferentially survive. Using a candidate-based approach to identify effectors of invasion-associated resistance, we targeted beta 1 and alpha V beta 3/beta 5 integrins, essential extracellular matrix receptors in mesenchymal tumors, which mediate cancer progression and resistance. Combining radiotherapy with beta 1 or alpha V integrin monotargeting in invading tumors led to relapse and metastasis in 40-60% of the cohort, in line with recently failed clinical trials individually targeting integrins. However, when combined, anti-beta 1/alpha V integrin dual targeting achieved relapse-free radiosensitization and prevented metastatic escape. Collectively, invading cancer cells thus withstand radiotherapy and DNA damage by beta 1/alpha V beta 3/beta 5 integrin cross-talk, but efficient radiosensitization can be achieved by multiple integrin targeting.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Haeger, AnnaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Alexander, StephanieUNSPECIFIEDorcid.org/0000-0002-8308-3977UNSPECIFIED
Vullings, ManonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kaiser, Fabian M. P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Veelken, CorneliaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Flucke, UtaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Koehl, Gudrun E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hirschberg, MarkusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Flentje, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hoffman, Robert M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Geissler, Edward K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kissler, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Friedl, PeterUNSPECIFIEDorcid.org/0000-0002-0119-4041UNSPECIFIED
URN: urn:nbn:de:hbz:38-351060
DOI: 10.1084/jem.20181184
Journal or Publication Title: J. Exp. Med.
Volume: 217
Number: 1
Date: 2020
Publisher: ROCKEFELLER UNIV PRESS
Place of Publication: NEW YORK
ISSN: 1540-9538
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CIRCULATING TUMOR-CELLS; MONOCLONAL-ANTIBODY; RADIATION-THERAPY; HUMAN-MELANOMA; IN-VITRO; DNA; RESISTANCE; GROWTH; RADIOTHERAPY; BETA-1-INTEGRINMultiple languages
Immunology; Medicine, Research & ExperimentalMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/35106

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item